Finoriq research workspace
ACTUATE THERAPEUTICS, INC. (ACTU) SEC Filings & Filing Highlights
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for. Review ACTU SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
- Company
- ACTUATE THERAPEUTICS, INC. (ACTU)
- Ticker
- ACTU
- Market Cap
- $33.4M
- Latest Price
- $1.395
- Industry
- Biotech & Pharma
ACTUATE THERAPEUTICS, INC. (ACTU) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ACTUATE THERAPEUTICS, INC. (ACTU).
| Event | Form | Date |
|---|---|---|
| The voting results with respect to the election of each director were as followsOn May 21, 2026, Actuate Therapeutics, Inc. (the “Company”) hosted its Annual Meeting of Stockholders (“Annual Meeting”) virtually. At the... | 8-K5.07 | 2026-05-22 |
| Actuate Therapeutics Announces FDA Clearance of IND for Oral ElraglusibActuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib | 8-K7.01 | 2026-05-11 |
| Actuate Therapeutics Announces Key AppointmentActuate Therapeutics Announces Key Appointment | 8-K8.01 | 2026-05-06 |
| On May 1, 2026, the Board of Directors (“Board”) of Actuate Therapeutics, Inc. (the “Company”),...On May 1, 2026, the Board of Directors (“Board”) of Actuate Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating a... | 8-K5.02 | 2026-05-06 |
| Actuate Therapeutics Reports Positive Follow-Up Data from its RandomizedActuate Therapeutics Reports Positive Follow-Up Data from its Randomized | 8-K7.01 | 2026-01-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.